MAAT INDEX

CLAIM #21015 · DHR (DHR) · 2026Q1 earnings call · Apr 21, 2026 · due Dec 31, 2026

And then the other thing here that we talked about on the respiratory side, we probably need to see a little bit above normal respiratory season to finish the year here in Q4 back to that kind of endemic $1.8 billion rate that we see going forward.

Matthew Gugino · CFO

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Respiratory segment annual revenue rate, full fiscal year

It came true if: Full-year respiratory revenue >= $1.8 billion

Where: Company-disclosed segment/product line revenue (10-K or Q4 earnings call commentary)

In context

st, you need to see some further improvement across the Life Sciences end markets. I think we're encouraged by what we saw here in Q1, but we need to see some of those policy headwinds further abate, especially in the U.S. and what we've seen there. I think China, good start to the year, but we need to see further growth acceleration as well. And then on the biotech funding side, again, starting to see some improvement, but we want to see that funding turn more quickly into orders. I think the second thing, bioprocessing, we probably need to see it a little bit better than the high single-digit growth. We need to accelerate on the consumable side as well as get that equipment growth going here, again, encouraged by the order patterns, but probably need to see it move a little bit quicker. And then the other thing here that we talked about on the respiratory side, we probably need to see a little bit above normal respiratory season to finish the year here in Q4 back to that kind of endemic $1.8 billion rate that we see going forward. So I think all in all, we're encouraged by the start to the year. We're already at 3% ex respiratory today and encouraged to see some of the underlying trends improve as we talked about. Rainer Blair: And Doug, as it relates to M&A, we have both the balance sheet capacity as well as the leadership bandwidth here to execute additional acquisitions in any of the 3 segments and feel very good about how we've positioned our talent and develop that talent in order to be able to do that. Operator: We've now reached our allotted time for questions. So I'll turn the call back over to management for any additional or closing remarks. Rachel Vatnsdal: No, perfect. That is all we have. You can reach us with questions today. Thank you so much for joining. Rainer Blair: Thanks, everyone. Operator: Tha

Verify independently

SEC filings for DHR · Claim quote is verbatim from the 2026Q1 earnings call.